Transcriptional Analysis for Synergistic Drug Identification in AML

Zamari Niazi^*
*Correspondence: Zamari Niazi, Department of Pharmacy, University of Illinois, Chicago, IL 61820, USA, Email:

Keywords

Acute Myeloid Leukemia (AML) • Chemotherapy • Gene expression profiling • Drug

Introduction

AML is a highly heterogeneous disease, meaning that it can manifest differently in different patients. This heterogeneity poses a significant challenge in developing effective treatments because a one-size-fits-all approach may not be suitable. Transcriptional analysis helps researchers unravel this heterogeneity by identifying distinct molecular subtypes of AML based on gene expression patterns. Researchers have classified AML into several molecular subgroups, such as those with specific genetic mutations like FLT3-ITD, NPM1, and RUNX1. These subgroups have different prognoses and responses to treatment, making it essential to tailor therapies to individual patients. Transcriptional analysis allows clinicians to identify the molecular subtype of AML in each patient, guiding treatment decisions and increasing the chances of a favorable outcome. One of the primary benefits of transcriptional analysis in AML research is its ability to pinpoint dysregulated biological pathways. AML cells often hijack normal cellular processes to fuel their uncontrolled growth. By analyzing gene expression patterns, researchers can identify the specific pathways that are overactive or suppressed in AML, offering valuable insights into the disease's biology [1].

Literature Review

A study might reveal that a particular signaling pathway related to cell proliferation is hyperactive in AML cells. This information can guide the selection of targeted therapies that specifically inhibit that pathway, potentially slowing down the cancer's growth. Conversely, if a pathway responsible for DNA repair is suppressed, it may suggest vulnerabilities that can be exploited with DNA-damaging drugs. Transcriptional analysis also helps researchers discover novel drug targets by identifying genes that are consistently dysregulated in AML but not in healthy cells. These genes may represent potential therapeutic targets that can be exploited to develop new drugs or repurpose existing ones for AML treatment. Transcriptional analysis has paved the way for personalized medicine in AML. By profiling the gene expression patterns of individual patients, clinicians can tailor treatment strategies to match the unique characteristics of their disease. Personalized medicine offers the potential to maximize treatment efficacy while minimizing side effects [2].

Transcriptional analysis reveals that a patient's AML cells have a specific gene mutation that drives their growth, targeted therapies designed to inhibit that mutation can be administered. In cases where multiple genetic aberrations are present, combination therapies can be developed, taking advantage of the synergy between different drugs to achieve a more potent anti-cancer effect. One of the most promising applications of transcriptional analysis in AML research is the identification of synergistic drug combinations. AML is notorious for its ability to develop resistance to single-agent therapies, making combination therapies an attractive strategy to overcome this challenge. Transcriptional analysis can help identify genes and pathways that are commonly dysregulated in AML samples. By cross-referencing this information with existing databases of drug-gene interactions, researchers can predict which drugs may be effective in targeting these dysregulated pathways. The key is to find drugs that, when used in combination, have a synergistic effect, meaning their combined efficacy is greater than the sum of their individual effects [3].

Discussion

AML is known for its ability to develop resistance to treatment, including combination therapies. Researchers must continually adapt and modify drug combinations to stay ahead of resistance mechanisms. In silico analysis, using computational models, has become an indispensable tool in predicting drug synergies based on transcriptional data. These models take into account the complex interactions between genes and drugs to suggest potential combinations that are more likely to be effective. This approach saves time and resources by prioritizing drug combinations for further experimental validation. Once potential synergistic drug combinations are identified through transcriptional analysis and computational modeling, they must be rigorously tested in the laboratory. This involves conducting preclinical studies using AML cell lines and animal models to assess the safety and efficacy of the drug combinations. In these experiments, researchers evaluate the impact of the drug combinations on AML cell viability, proliferation, and apoptosis (cell death). They also examine the drugs' effects on normal blood cells to ensure that they are specific to AML cells [4].

Promising combinations can then proceed to clinical trials to evaluate their effectiveness in human patients. Integrating data from different sources, such as gene expression profiles, drug databases, and clinical outcomes, can be complex. Developing robust bioinformatics pipelines is crucial for accurate analysis. Translating promising laboratory findings into clinically effective treatments is a lengthy and costly process. Clinical trials are needed to confirm the safety and efficacy of identified drug combinations. AML is highly heterogeneous, and drug responses can vary widely among patients. Tailoring treatment to individual patients based on their unique molecular profiles remains a challenge [5,6].

Conclusion

Transcriptional analysis has emerged as a powerful tool in AML research, enabling researchers to dissect the disease's heterogeneity, identify dysregulated pathways, and develop personalized treatment strategies. Moreover, it holds significant promise in the identification of synergistic drug combinations that can enhance treatment efficacy and overcome drug resistance.As our understanding of the molecular underpinnings of AML continues to grow, so does the potential for transcriptional analysis to revolutionize AML treatment. By harnessing the insights gained from transcriptional analysis and combining them with innovative drug discovery approaches, we can look forward to a future where AML becomes a more manageable and treatable disease, ultimately improving the lives of patients facing this challenging diagnosis.

Acknowledgement

None.

Conflict of Interest

None.

References

1. More, Piyush, Joëlle Aurelie Mekontso Ngaffo, Ute Goedtel-Armbrust and Patricia S. Hähnel, et al. "Transcriptional response to standard AML drugs identifies synergistic combinations." Int J Mol Sci 24, (2023): 12926.

   Google Scholar, Crossref, Indexed at

2. Dzama, Margarita M., Marlene Steiner, Johanna Rausch and Daniel Sasca, et al. "Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition." Am J Hematol 136 (2020): 2442-2456.

   Google Scholar, Crossref, Indexed at

3. Uras, Iris Z, Gina J. Walter, Ruth Scheicher and Florian Bellutti, et al. "Palbociclib treatment of FLT3-ITD+ AML cells uncovers a kinase-dependent transcriptional regulation of FLT3 and PIM1 by CDK6."Am J Hematol 127 (2016): 2890-2902.

   Google Scholar, Crossref, Indexed at

4. Lai, Y. S, J. Y. Chen, H. J. Tsai and T. Y. Chen, et al. "The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells." Blood Cancer J 5 (2015): e313-e313.

   Google Scholar, Indexed at

5. Maslah, Nabih, Norman Salomao, Louis Drevon, Emmanuelle Verger, Nicolas Partouche, Pierre Ly, Philippe Aubin et al. "Synergistic effects of PRIMA-1Met (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia." Haematologica 105 (2020): 1539.

   Google Scholar, Crossref, Indexed at

6. Chen, Zhe, Qian Guo, Shichen Huang and Lei Li, et al. "Overcoming adaptive resistance in AML by synergistically targeting FOXO3A-GNG7-mTOR axis with FOXO3A inhibitor Gardenoside and rapamycin." Genes Dis 11 (2024): 397-412.

   Google Scholar, Crossref, Indexed at